Aqemia
Aqemia combines physics-based calculations with generative artificial intelligence to invent new drug molecules, working both on its own projects and with large drug companies such as Sanofi.
Overview
Aqemia, founded in 2019 and headquartered in Paris with an office in London, uses deep physics (quantum and statistical mechanics calculations of binding affinity) coupled with generative AI to design and optimise small molecules without relying on large experimental training sets. The company pursues a mix of wholly owned programmes, which it says typically show superior efficacy and non-toxicity in vivo, and partnered programmes; its strategies include broad exploration across many targets and indication-first moonshots for single diseases of high unmet need. Sanofi expanded its research collaboration with Aqemia in July 2026. The fetched pages do not list specific targets or indications, so the oncology content of the pipeline and the company's financing rounds could not be confirmed from primary sources.
Notes
top- Oncology focus not confirmed on fetched pages (pipeline page gives no programmes). Series B (2024) not sourced, so omitted; stage set to startup.